据报巴西正洽谈额外增购2,000万剂科兴疫苗
《路透》报道,巴西正洽谈额外购买中国科兴(SVA.US)开发的2,000万剂新冠病毒疫苗。
报道引述巴西圣保罗州州长多Joao Doria表示,此将是早前订购的1亿剂科兴「CoronaVac」疫苗之外的新订单。而巴西国营机构布坦坦研究所(Butantan Institute)已经获得「CoronaVac」疫苗。
该研究所领导巴西对科兴疫苗的大规模临床测试,目前正在为一项全国免疫计划分装疫苗,计划在明年初实现100%在国内生产。而另一种获准在巴西紧急使用的新冠疫苗是英国阿斯利康(AZN.US)疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.